Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

Related Articles by Review for PubMed (Select 22025779)

1.

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy.

Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD.

Diabetes. 2011 Nov;60(11):3055-66. doi: 10.2337/db11-0807.

2.

Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy.

Li B, Liu S, Miao L, Cai L.

Exp Diabetes Res. 2012;2012:216512. doi: 10.1155/2012/216512. Epub 2012 May 8. Review.

3.

Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much?

Tan SM, de Haan JB.

Redox Rep. 2014 May;19(3):107-17. doi: 10.1179/1351000214Y.0000000087. Epub 2014 Feb 21. Review.

PMID:
24559141
4.

The role of ubiquitination and sumoylation in diabetic nephropathy.

Gao C, Huang W, Kanasaki K, Xu Y.

Biomed Res Int. 2014;2014:160692. doi: 10.1155/2014/160692. Epub 2014 Jun 4. Review.

5.

A glimpse of various pathogenetic mechanisms of diabetic nephropathy.

Kanwar YS, Sun L, Xie P, Liu FY, Chen S.

Annu Rev Pathol. 2011;6:395-423. doi: 10.1146/annurev.pathol.4.110807.092150. Review.

6.

A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity.

Limonciel A, Jennings P.

Toxins (Basel). 2014 Jan 20;6(1):371-9. doi: 10.3390/toxins6010371. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk